Companies /Healthcare

Editas Medicine Inc

NASDAQ: EDIT Biotechnology
$1.71
▼ $0.06 (−3.39%) today
Markets closed · 3:03am ET

EDIT at a Glance

Valuation
Market cap
$273.2M
Profitability
Revenue (TTM)
$49.8M
Profit margin
-145.0%
EPS (TTM)
$-0.54
Price
52-week range
$2 – $4
Street target
$6.10

Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: EDIT editasmedicine.com

About Editas Medicine

Editas Medicine is a clinical-stage gene editing company that uses CRISPR genome editing systems to develop durable, precision in vivo medicines for serious diseases. Its lead candidate, EDIT-401, is an experimental in vivo therapy for hyperlipidemia. It uses an upregulation approach that edits the LDLR gene to increase LDLR protein expression and lower LDL-C. EDIT-401 is entering the Phase 1/2 Strive study in patients with Heterozygous Familial Hypercholesterolemia in Australia. The company is also developing a targeted lipid nanoparticle (tLNP) platform for extrahepatic delivery, including in vivo delivery of mRNA to T-cells. Editas is the exclusive licensee of the Broad Institute's Cas12a patent estate and of the Broad Institute and Harvard University Cas9 patent estates for human medicines. It earns collaboration and other R&D revenue from partnerships and licensing, including milestones from its Bristol Myers Squibb collaboration. Under that collaboration, BMS is developing alpha-beta T cell medicines such as BMS-986527, a CD70 healthy-donor allogeneic CAR-T therapy engineered with Editas' Cas12a technology. Updated

EDIT Coverage

Frequently Asked Questions

What does Editas Medicine do?

Editas Medicine is a clinical-stage gene editing company that uses CRISPR genome editing systems to develop durable, precision in vivo medicines for serious diseases. Its lead candidate, EDIT-401, is an experimental in vivo therapy for hyperlipidemia.

What is the EDIT stock price target?

The Wall Street consensus 12-month price target for EDIT is $6.10.